@entity2247 and @entity7 ( @entity7 ) have been reported to be significantly related to @entity5 . However, there has been no report on the relation between @entity2247 and @entity7 overexpression in @entity788 . We investigated the overexpression of @entity2247 and @entity7 immunohistochemically in @entity5 ( @entity5 ) and @entity513 ( @entity513 ) and examined the relationship with clinicopathological factors and the correlation between these immunoactivities in @entity5 and @entity513 . In @entity5 , the positive rates of @entity2247 overexpression were 0% in 10 areas of @entity1373 , 54.5% of @entity652 , 83.3% of intraductal areas of @entity420 , and 66.7% of invasive areas of @entity420 . On the contrary, 47.8% of @entity513 were positive for @entity2247 overexpression. The positive rates of @entity7 in @entity5 were 10% in areas of @entity1373 , 54.5% of @entity652 , 66.7% of intraductal areas of @entity420 and 66.7% of invasive areas of @entity420 . However, in @entity513 it was 47.8%. Only lymph node metastasis correlated significantly with @entity7 overexpression (p=0.04), while the other factors had no significant relationships with either @entity2247 or @entity7 overexpression. There was a statistically significant correlation between @entity2247 and @entity7 overexpression in @entity5 (p<0.001), in 5 @entity1 with @entity652 of which both @entity2247 and @entity7 were stained in almost exactly the same locations. On the contrary, @entity2247 and @entity7 overexpression had no statistically significant relationship in @entity513 . In conclusion, we demonstrate evidence of @entity2247 and @entity7 overexpression in @entity1 @entity788 . Chemoprevention via the suppression of angiogenesis by means of @entity2247 inhibitor may be more effective in @entity5 than in @entity513 , because of the strong correlation of both factors especially in @entity5 .

Expression of cyclooxygenase-2 and @entity7 in XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic tumors'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['carcinogenesis or progression of various cancers', 'intraductal papillary-mucinous tumors', 'IPMT'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia'] @entity513 :: ('MESH:D044584', 'Disease') :: ['IDC', 'invasive ductal carcinoma'] @entity2247 :: ('4513', 'Gene') :: ['COX-2', 'Cyclooxygenase (COX)-2'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenoma'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic tumors']
